logo
Select company
Select metric
72.03%Cash to Assets Ratio
VS
Market
95
Sector
84
Industry
76
History
3
$ 2.54Close
$ 1.18 - $ 11.68 52-Week Range
Ticker Information

Ticker

BTAI

Company Name

BIOXCEL THERAPEUTICS INC

Sector

Healthcare

Industry

Biotechnology

Exchange

NASDAQ

BIOXCEL THERAPEUTICS INC - Cash to Assets Ratio Chart Analysis (TTM)

From
Zoom
1Y
3Y
5Y
10Y

BTAI - Cash to Assets Historical data
DateTotal AssetsCash and EquivalentsCash to Assets Ratio
6/30/2025$ 25.79M$ 18.57M72.03%
3/31/2025$ 38.57M$ 31.01M80.42%
12/31/2024$ 38.34M$ 29.85M77.87%
9/30/2024$ 48.89M$ 40.39M82.6%
6/30/2024$ 65.44M$ 56.27M86%
3/31/2024$ 82.32M$ 74.14M90.06%
12/31/2023$ 73.7M$ 65.22M88.49%
9/30/2023$ 100.45M$ 89.96M89.56%
6/30/2023$ 140.1M$ 127.55M91.04%
3/31/2023$ 180.1M$ 165.52M91.9%
Previous (option currently disabled)
1 (current)
Next (option currently disabled)

Key Performance Insights, Last 5 Years

  • BIOXCEL THERAPEUTICS INC's latest trailing twelve months (TTM) Cash to Assets stands at 97.77%.
  • Over the past 5 years, BIOXCEL THERAPEUTICS INC's average Cash to Assets has been 90.53%.
  • The median Cash to Assets for BIOXCEL THERAPEUTICS INC during this period was 92.97%
  • BIOXCEL THERAPEUTICS INC reached its highest Cash to Assets over the past 5 years at 97.77%.
  • The lowest Cash to Assets recorded by BIOXCEL THERAPEUTICS INC in the same timeframe 72.03%

BIOXCEL THERAPEUTICS INC's Cash to Assets vs. competitors

We picked the following companies as peers based on multiple factors, including sector, industry, market capitalization and revenue

Cash to Assets Benchmarks
CompanyCash to Assets
VTGN : VISTAGEN THERAPEUTICS INC 71.07%COYA : COYA THERAPEUTICS INC 88.95%AVTX : AVALO THERAPEUTICS INC 33.42%ADVM : ADVERUM BIOTECHNOLOGIES INC 46.16%RNXT : RENOVORX INC 90.26%OTLK : OUTLOOK THERAPEUTICS INC 39.75%ABVC : ABVC BIOPHARMA INC 6.63%SONN : SONNET BIOTHERAPEUTICS HOLDINGS INC 15.63%RLYB : RALLYBIO CORP 18.52%DTIL : PRECISION BIOSCIENCES INC 77.86%

Definition of Cash to Assets Ratio

[Calculation] The Cash to Assets Ratio expresses a company’s cash and cash equivalents [CashnEq] as a percentage of total [Assets].
CashnEq / Assets
(=) Cash to Assets
Cash to Assets for BIOXCEL THERAPEUTICS INC is calculated as follows: CashnEq [ $ 233.43M ] / Assets [ $ 238.75M ]
(=) Cash to Assets [ 97.77% ]

BTAI - Cash to Assets Ratio, Last 5 years

72.03%

Minimum

Jun 30, 2025

97.77%

Maximum

Sep 30, 2020

90.53%

Average

92.97%

Median

Cash to Assets Benchmark Analysis

The chart above depicts the distribution of Cash to Assets for companies in the Total Stock Market. The average Cash to Assets of the companies is 9.76% with a standard deviation of 9.51%.
The following table provides additional summary stats:
Cash to Assets in the Market:
filtered constituents3.94K
min0%
max40.71%
average9.76%
median6.41%
std9.51%